Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Pacific Biosciences of California, Inc.

Market Cap 410M 360M 332M 311M 582M 38.84B 592M 3.99B 1.54B 19.06B 1.54B 1.51B 66.23B P/E 2026 *
-3.22x
P/E 2027 * -2.82x
Enterprise Value 410M 360M 332M 311M 582M 38.84B 592M 3.99B 1.54B 19.06B 1.54B 1.51B 66.23B EV / Sales 2026 *
2.44x
EV / Sales 2027 * 2.12x
Free-Float
91.23%
Yield 2026 *
-
Yield 2027 * -
1 week+0.73%
Current month-7.12%
1 month+10.29%
3 months+4.24%
6 months-24.19%
Current year-21.11%
1 week 1.11
Extreme 1.1125
1.24
1 month 1.03
Extreme 1.0322
1.48
3 years 0.75
Extreme 0.7537
12.97
Manager TitleAgeSince
Chief Executive Officer 58 2020-09-13
Director of Finance/CFO 57 2025-03-30
Chief Operating Officer 53 2021-01-07
Director TitleAgeSince
Director/Board Member 67 2003-12-31
Director/Board Member 72 2008-12-31
Director/Board Member 69 2012-01-17
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+0.73%+6.27%-90.00% 410M
+1.15%-0.69%+17.28%-10.47% 172B
+0.06%-3.33%-21.73%+23.20% 143B
+0.44%-1.31%-8.85%-24.86% 126B
+2.86%-2.81%-55.45%-15.51% 65.89B
+1.25%-1.84%+15.44%-3.75% 49.45B
+0.06%-1.26%-25.33%-31.86% 44.05B
+0.14%-1.30%+9.08%+6.07% 35.72B
-0.29%-0.93%+4.19%+37.47% 35.18B
+5.08%+0.77%-10.46%-20.17% 27.58B
Average +1.02%-2.49%-6.96%-12.99% 77.68B
Weighted average by Cap. +0.89%-2.43%-7.23%-4.72%

Financials

2026 *2027 *
Net sales 168M 147M 136M 127M 238M 15.9B 242M 1.63B 631M 7.8B 630M 616M 27.11B 194M 170M 157M 147M 275M 18.36B 280M 1.88B 729M 9.01B 728M 712M 31.31B
Net income -129M -113M -104M -97.43M -183M -12.18B -186M -1.25B -484M -5.98B -483M -472M -20.77B -149M -131M -120M -113M -211M -14.08B -215M -1.44B -559M -6.91B -558M -546M -24.01B
Net Debt - -
Logo Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Employees
-
Date Price Change
26-06-23 1.140 -2.36%
26-06-22 €1.168 -1.68%
26-06-19 €1.188 -2.42%
26-06-18 €1.217 +2.44%
26-06-17 €1.188 +3.30%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.320USD
Average target price
2.458USD
Spread / Average Target
+86.24%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!